Single-Cell Transcriptomics of Human and Mouse Lung Cancers Reveals Conserved Myeloid Populations across Individuals and Species
Tumor-infiltrating myeloid cells (TIMs) comprise monocytes, macrophages, dendritic cells, and neutrophils, and have emerged as key regulators of cancer growth. These cells can diversify into a spectrum of states, which might promote or limit tumor outgrowth but remain poorly understood. Here, we use...
Saved in:
Published in | Immunity (Cambridge, Mass.) Vol. 50; no. 5; pp. 1317 - 1334.e10 |
---|---|
Main Authors | , , , , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
Elsevier Inc
21.05.2019
Elsevier Limited |
Subjects | |
Online Access | Get full text |
ISSN | 1074-7613 1097-4180 1097-4180 |
DOI | 10.1016/j.immuni.2019.03.009 |
Cover
Summary: | Tumor-infiltrating myeloid cells (TIMs) comprise monocytes, macrophages, dendritic cells, and neutrophils, and have emerged as key regulators of cancer growth. These cells can diversify into a spectrum of states, which might promote or limit tumor outgrowth but remain poorly understood. Here, we used single-cell RNA sequencing (scRNA-seq) to map TIMs in non-small-cell lung cancer patients. We uncovered 25 TIM states, most of which were reproducibly found across patients. To facilitate translational research of these populations, we also profiled TIMs in mice. In comparing TIMs across species, we identified a near-complete congruence of population structures among dendritic cells and monocytes; conserved neutrophil subsets; and species differences among macrophages. By contrast, myeloid cell population structures in patients’ blood showed limited overlap with those of TIMs. This study determines the lung TIM landscape and sets the stage for future investigations into the potential of TIMs as immunotherapy targets.
[Display omitted]
•Human dendritic cell and monocyte subsets show one-to-one equivalence in mouse•Neutrophils exhibit tumor-associated phenotypes that are conserved across species•Myeloid subsets in patient blood only partially overlap with those in their tumors•Unique markers define myeloid cell subsets and associate with clinical prognosis
Tumor-infiltrating myeloid cells (TIMs) have emerged as key cancer regulators and potential next-generation immunotherapy targets, yet they remain incompletely understood. Using scRNA-seq, Zilionis et al. map the TIM landscape in human and murine lung tumors and systematically compare cell states, revealing conserved myeloid populations across individuals and species. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 Lead Contact: Allon M. Klein RZ, CE, CP, VS, MJP and AMK initiated the study, performed the analyses, prepared the figures and wrote the manuscript. CE and CP carried out mouse experiments and prepared mouse samples. RZ and VS carried out scRNA-Seq experiments and computational analyses. DZ developed the Bayesian classifier and assisted in data analysis. HDS performed RNA in situ hybridization and immunohistochemical analysis on patient tumor sections. CVM, CMK, SC, WGR, ADR, IK, GM, EL, DGT, and RB obtained and prepared human patient samples, specifically: CVM, CMK and SC consented patients, maintained IRB approval, obtained blood, gathered clinical data and provided the specimens; WGR, ADR helped in the design of sample collection, provided infrastructure and quality assurance; RB supervised human sample collection and processing, initiated the collaboration, reviewed the work and provided clinical context. IK and GM processed patient samples; EL and DGT initiated the collaboration and coordinated patient sample experiments. AMK and MJP supervised the study. These authors contributed equally Author contributions |
ISSN: | 1074-7613 1097-4180 1097-4180 |
DOI: | 10.1016/j.immuni.2019.03.009 |